ATR and cancer: Inactivating Rad51 in the homologous recombination repair (HR) pathway led to differential sensitivity of MCF-7 and Hela cells to ATR and CHK1 inhibitors, implicating ATR and CHK1 as potential drug targets for HR-defective cancers [51].